The University of Akron

IdeaExchange@UAkron
Williams Honors College, Honors Research
Projects

The Dr. Gary B. and Pamela S. Williams Honors
College

Spring 2021

Minimally Invasive Repair of Elongated Chordae Tendineae in the
Mitral Valve
Walid Abuhashim
The University of Akron, waa23@zips.uakron.edu

Diana Albaba
The University of Akron, da97@zips.uakron.edu

Austin Ghiates
The University of Akron, atg34@zips.uakron.edu

Rebecca Leiter
The University of Akron, rml68@zips.uakron.edu

Mary Robakowski
The University of Akron, mer101@zips.uakron.edu
Follow this and additional works at: https://ideaexchange.uakron.edu/honors_research_projects
Part of the Biomedical Engineering and Bioengineering Commons, and the Medical Sciences
Commons

Please take a moment to share how this work helps you through this survey. Your feedback will
be important as we plan further development of our repository.
Recommended Citation
Abuhashim, Walid; Albaba, Diana; Ghiates, Austin; Leiter, Rebecca; and Robakowski, Mary, "Minimally
Invasive Repair of Elongated Chordae Tendineae in the Mitral Valve" (2021). Williams Honors
College, Honors Research Projects. 1414.
https://ideaexchange.uakron.edu/honors_research_projects/1414
This Dissertation/Thesis is brought to you for free and open access by The Dr. Gary B. and Pamela
S. Williams Honors College at IdeaExchange@UAkron, the institutional repository of The University
of Akron in Akron, Ohio, USA. It has been accepted for inclusion in Williams Honors College,
Honors Research Projects by an authorized administrator of IdeaExchange@UAkron. For more
information, please contact mjon@uakron.edu, uapress@uakron.edu.

Minimally Invasive Repair of Elongated Chordae
Tendineae in the Mitral Valve
Walid Abuhashim
Biomedical Engineering
Department
The University of Akron
Akron, U.S.A.
waa23@uakron.edu

Diana Albaba
Biomedical Engineering
Department
The University of Akron
Akron, U.S. A
da97@uakron.edu

Austin Ghiates
Biomedical Engineering
Department
The University of Akron
Akron, U.S.A
atg34@uakron.edu

Abstract - In the United States, about 4 million people have
been estimated to suffer from severe mitral valve
regurgitation [5]. Due to the high risks involved, about half
of those patients are ineligible for surgery to repair the valve,
because of their poor health [6]. Elongation of the chordae
tendineae has been found to be one of the significant causes
of regurgitation. To address this, the team has developed a
device called “Chord Fastener”, which will restore proper
function to the valve via shortening of the chordae tendineae
[1]. Via this shortening mechanism, the device will reduce
mitral valve regurgitation and will be used in a minimally
invasive cardiac procedure. Over the course of two academic
semesters, the design and testing of the Chord Fastener was
undertaken. The resulting prototype has demonstrated good
promise that with refinement, it can function as intended
and meet the project requirements.
I. INTRODUCTION
Approximately four million people in the United States suffer
from mitral regurgitation [1]. Mitral regurgitation occurs when
the mitral valve does not close properly, allowing blood to
flow backwards from the left ventricle into the left atrium.
Improper mitral valve closing is a result of deterioration or
elongation of the chordae tendineae (CT). The CT are fibrous
biological chords that attach the mitral valve leaflets to the
papillary muscle. In normal physiology, the papillary muscle
contracts during asystole, pulling the CT to close the mitral
valve. If the CT are not functioning properly, for instance due
to elongation, the valve does not close properly, and blood is
allowed back into the left atrium (4). Currently, pathological
chordae tendineae can be repaired through open heart surgery.
However, due to open heart surgery’s rigorous nature on the
body, only 50% of the patients needing open heart surgery to
resolve a leaky heart valve, undergo the valve repair due to
age or poor health [2].
Current options to treat mitral valve regurgitation include a
replacement or a repair of the valve. Because of how it
prolongs life expectancy, improves lifestyle, and minimizes

May 2021

Rebecca Leiter
Biomedical Engineering
Department
The University of Akron
Akron, U.S.A
rml68@uakron.edu

Mary Robakowski
Biomedical Engineering
Department
The University of Akron
Akron, U.S.A
mer101@uakron.edu

risk of infection, repair of the valve is more ideal than
replacement of a valve [3]. To repair the valve, moderately
invasive methods that consist of small incisions to the chest
are currently most popular [4]. However, there are a couple of
current options for addressing mitral valve regurgitation using
minimally invasive procedures. The MitraClip is a current
product manufactured by Abbott, while NeoChord, Inc. has a
product still under development. The Mitraclip is used via
insertion into the right ventricle of the heart to bind the leaflets
of the valve to minimize regurgitation [5]. In the NeoChord
technique, artificial chords are implanted into the heart
transeptally to attach to the valve leaflets and the papillary
muscle [9]. With only one minimally invasive mitral valve
repair device available to the biomedical market, the group
decided to investigate other approaches to solving the
problem. The resulting device was subsequently called the
“Chord Fastener”.
II. USER NEEDS
In the first stage of the design process, the main goal was to
perform background research to find a clinical problem that
requires a solution. The group chose to find a problem within
the cardiovascular area, so the team investigated potential
problems with heart valves. The team finally agreed upon the
clinical problems associated with mitral valve regurgitation.
Initially, the team wanted to improve the design of prosthetic
heart valves. Therefore, designs of current valve transplants
were investigated, as well as patents for prosthetic valves that
are being developed (refer to Appendix A for an image of
current prosthetic valve options).
After more research, and interviews with physicians and
professors, the team learned of the great need for a minimally
invasive solution and of the significant role elongated chords
played in regurgitation. Thus, it was decided to proceed with
developing a plan to target the elongated tendineae.
Alongside, the tortuous and lengthy nature of designing a
replacement valve was an additional contributing factor to the
decision to create a repair mechanism over a replacement
1

valve. The aim of the project was to develop a device to repair
the elongated chords that can be inserted in a minimally
invasive fashion (note: any reference to ‘minimally invasive’
in this report is referring to the procedure not the actual
device, and this criterion is not to be confused with “a
minimally invasive device”). This procedure would involve
repairing the elongated CT, as they were found to be a leading
cause of collapsing mitral valve leaflets [5]. Finally, this
procedure would be intended for patients who cannot undergo
open-heart surgeries to repair the mitral valve due to age or
other risk factors.

30.3, 11.4, and 12.6 respectively (when testing the device, the
values are used to evaluate whether the device passes or fails
each test.). These target values of force and cycling allow the
team to better quantify the engineering requirements.

From further interviews with cardiologists, a set of customer
requirements were determined. The customer requirements
were: (1) a minimally invasive procedure to implant the
device, (2) a safe, secure, and repeatable placement of the clip,
(3) ease of use, (4) low risk to the patient, (5)
hemocompatibility/biocompatibility, and (6) restoration of
proper tension to the leaflets of the valve. Achieving (1) a
minimally invasive procedure, (2) a safe, secure, and
repeatable placement, and (5) hemocompatibility/
biocompatibility were determined to be the 3 most important
customer requirements for the device.

The relationship between the procedure being “minimally
invasive” and the “use of a catheter” was determined to be
strong, because catheters have been found to have great
minimally invasive procedure qualities. For in a study of 250
individuals who had undertaken a cardiac surgery involving a
catheter very few individuals developed minor or serious
health complications [17]. Specifically, after a 3-year period,
less than 1% got stroke, and only 0.2% got femoral nerve
injury (the nerve in which the catheter would go through for a
chord tensioning procedure) [17].

III. DESIGN INPUTS
In the design inputs stage, a comprehensive set of engineering
requirements were developed. These were derived customer
requirements using the Quality Functional Deployment (QFD)
method. A preliminary risk assessment was also created at this
stage, (refer to appendix B for the full QFD document).
Engineering requirements are measurable and quantitative
attributes that address customer requirements. These were
assessed using the QFD approach to ensure that all user needs
were satisfactorily addressed by at least one engineering
requirement, and that quantitative target values were assigned.
The relationships between engineering and customer
requirements were determined and ranked as weak, moderate
or strong based on readings from literature. (See Appendix B
for the full QFD.)
Specific engineering requirements as inputs for our design
were: (1) use of a catheter to implant, (2) tension of 0.22 ±
0.09 N for primary CT and 0.69 ± 0.37 N for secondary CT
[13], (3) material composition to produce a moderate to low
activation of the coagulation pathway, and (4) material
durability against cycling over 200,000 cycles/day without
failure. The required tension range of .22- .69 N range were
derived from the average corresponding max and min tensions
in a human heart [4]. Moderate to low activation was defined
as less protein adsorption of fibrinogen to the device surface
than that of Biolon, and less coagulation activation than that of
glass (Biolon and Glass being known for their bad
hemocompatibility properties). The 200,000/day-number
requirement was found by applying a minimum safety factor
of 2 to the average human number of beats per day (100,000
beats per day) [15]. By taking these correlations, the relative
weights of the functional requirements were found to be 54.8,
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To decide the relative importance of each engineering
requirement, the relationships between engineering and
customer requirements were determined. These were
categorized as strong, moderate, or weak, where weak
indicated they have little to no correlation. Requirements with
strong correlations to the most important customer
requirements were given priority in the design process.

The relationship between the “device being biocompatible/
hemocompatible” and whether the material causes clotting
was determined to be strong. One material choice that was
considered was Nitinol, a nickel-titanium alloy. In a Smith &
Nephew study done on the hemocompatibility properties of
different materials, it found that Nitinol has a significant effect
on the protein adsorption and the effective activation of the
coagulation pathway. By exposing different metals to a dilute
blood plasma, it was found that depending on the metal used
prekallikrein, a key initiator to the coagulation cascade, could
vary from as low as 0.2 (moD/min/cm2) for pyrolytic carbon,
and to as high as 5 (moD/min/cm2) for Zr-2.5Nb [18]. This
indicates that the material choice and hemocompatibility/
biocompatibility would have a strong relationship.
Additionally, data from a Smith and Nephew study was used
to support the biocompatibility of Nitinol. The data is supplied
and discussed further in section VI.
The relationship between the requirement of “safe, secure and
repeatable placement” and “composition of the clip will
produce a moderate to low activation of the coagulation
pathway” was found to be moderate. The competitive device,
MitraClip, is also made of Nitinol and was proven to be safe
in a study performed over the course of 5 years [16, 19]. At
the one-year timepoint, 0.0% of patients experienced
thrombosis, 2.4% of patients experienced atrial septal defect,
2.4% of patients experienced mitral valve stenosis, 1.6% of
patients experienced non-cerebral thromboembolism, and
7.1% of patients experienced major vascular complications
[16].
The engineering requirements for our project were
implemented into the QFD (Appendix B). They are as follows:
(1) Catheter diameter 8 mm. (2) Chord tension 0.22 ± 0.09 N
for primary CT and 0.69 ± 0.37 for secondary CT [13]. (3)
The material shall not cause activation of coagulation cascade.
2

(4) The material shall be able to withstand 200,000 cycles/day
(1 cycle defined as 1 stretching/ loading followed by an
unloading of the sample). The importance (weight) of each
requirement were calculated through the QFD after assigning
relationships.
Because this device is intended for cardiac use, several severe
risks were identified. Major concerns included the potential
for blood clotting caused by the material, whether the device
can withstand the required forces, and the possibility of the
device being incorrectly sized. Various risk mitigation
measures were also found, including using pre-approved
materials and components and extensive testing (See
Appendix D for the risk assessment).
IV. DESIGN PROCESS
Using our design inputs, the team moved forward in the third
gate of the design process to determine the most effective
method of fixing elongated chordae tendineae. To brainstorm,
the team used method 365. In method 365 each member
produced three ideas separately and then came together to add
more details or feedback to each idea. From here the team was
able to narrow down the best ideas from the brainstorming that
would best meet the design inputs. The best three ideas were:
(a) clipping the chords, (b) stapling the chords, and (c) a mesh
wiring system to reinforce the valves. These three ideas were
then compared using the previous QFD. In the QFD matrix,
each idea was analyzed to see how well the device met both
the customer and engineering requirements.
The team made multiple QFD charts, one for each of the three
proposed methods. With each individual QFD chart the team
investigated how the proposed method and solution compared
with the design inputs from gate two (design input stage). The
proposed approach went through a second QFD. This second
QFD looked to compare the system and parts that go into the
solution to help evaluate the pieces against the engineering
requirements from gate two. The QFD process ultimately
evaluated each of the three approaches against the engineering
requirements to determine which one was best.
The finalized results of the QFD process (shown in the
Appendix B) showed that the best method to move forward
was binding the chords to shorten the length of elongated
chords. At this point, the success of the MitraClip in the
cardiac field was brought to the attention of the team through
interviews with cardiologists. The MitraClip is a pronged
clipping device used to clip the leaflets of the mitral valve
together, all through a minimally invasive procedure (an
approach that aligned with the team’s objective). This inspired
the team to redesign this clip for use specifically on the
elongated chords themselves rather than the leaflets (as in the
case of the MitraClip). It was reasoned that since regurgitation
can be due to the elongated chords, shortening them back to
their regular length, would allow the valve to close properly.
Thus, the team decided that this project would (1) bring about
a minimally invasive device to market to compete against the
MitraClip and (2) improve upon the MitraClip by resolving
May 2021

the actual cause of the regurgitation (elongated chords),
whereas the MitraClip aims to fix the valve itself.
After some research and the comparison to the engineering
requirements, the team determined preliminary engineering
specifications and sizing of the clip. The crown of the clip was
determined to be 2mm in thickness [14], the leg to be 2.5mm
long [14], the shaft of the catheter to be 6-8mm [14], and the
mechanism for opening the clip needing to be thin and
inelastic. From here, the team was able to move forward with
figuring out more specifications as well as making initial
prototypes.
V.

DESIGN OUTPUTS

Through the design process and the use of a decision matrix,
the team decided the best material to use is Nitinol, a nickeltitanium alloy that is approximately 56% nickel and 44%
titanium by weight. This material has proven to be valid for
many uses in biomedical engineering [18].
It was later determined that nickel-titanium was used in the
MitraClip, after an updated design was released in 2016 [19].
When compared to other materials considered for this project,
Nitinol had better mechanical properties and is more cost
effective. Nitinol is known to have a high fatigue strength, low
density, and is nonmagnetic. Also, it is very malleable and
therefore, can be used to manufacture very small devices.
When compared to stainless steel, nitinol has been shown to
be much stronger against deformation and is much more cost
effective than titanium 6-4 [11]. The design of the device is
based on the MitraClip but allows for easy use in the smaller
space while supporting the ability to add proper tension to the
chordae tendineae. The device does this by clipping to two
sections of the elongated chord and pinching it together to
shorten its effective length and restoring the proper tension. In
a general sense, the proposed device would be distinguished
from the MitraClip because of how it would shorten the CT
instead of the valve leaflets. As for technical differences, the
Chord Fastener would be smaller but provide a greater surface
area where the CT would be attached. Also, the MitraClip uses
thinner and longer hooks to secure it in place on the valve
leaflets while the Chord Fastener would use a smoother,
grooved section to avoid piercing the CT and causing more
damage. To operate the device, the user will pull on the center
shaft which opens the upper, grooved section of the clip and
allows the user more space to grab the CT. The user will then
place the device in a way where the elongated CT is folded on
itself, and the overall linear length is shortened. To close the
upper arms and pull the CT together, the user will apply a
small force via the delivery mechanism that pushes the center
shaft back into the base where a locking mechanism will hold
it in place (See appendix G and N). The grooves on the
exterior arms line up with similar grooves on the interior arm
to allow for increased surface area and grip of the CT. The
overall size of the final product would be 3.125mm x 4mm x
less than 11.5 mm (length, width, height). These dimensions
keep the device compatible with the MitraClip Delivery
System that uses a 16Fr catheter with an inner diameter of
3

approximately 5.5mm [4]. The 3D model presented is at an
8:1 scale model to allow for the device to be 3D printed with
ease as there are many small dimensions that are crucial to the
functionality of the device. (Appendix E, Appendix F for open
clip).
The materials needed for manufacturing of the final product
are listed below in the Bill of Materials (Appendix G).
Included in the MitraClip Package is all necessary guide
wires, catheters, and controls needed to properly implant the
Chord Fastener device.
VI. DESIGN VERIFICATION
To ensure that the design outputs of our device, the Chord
Fastener, met the design inputs, a series of testing was
undertaken as seen in Appendix C. The team began by testing
if the width of the crown of the clip was small enough to enter
the mitral valve, verification #1. The group tested this by
measuring the width of the clip with a caliper. The device’s
width was smaller than the diameter of the valve (device
width: 3.5 mm, valve diameter: 21mm), therefore passing the
test. Next, the group tested if the device could meet the
requirements of opening in the heart and closing. Since the
device was physically observed to open and close using the
spring mechanism it passed verifications #2 and #3. And since
when it was in the open position the tip-to-tip measurement,
via caliper, was less than 4 cm, it passed the verification #4.
Because the clip’s closure mechanism was seen to be
retractable, via use of spring, it allowed the device to close in
a succinct manner passing the verification #5. When in the
closed position the clip had to be able to grab an at minimum
of 3 chordae tendineae. Since the clip had 3 grooves our
device passed this verification #6. Then to ensure that the clip
still is locked in placed once it has grabbed the chordae
tendinea, a series of weights were strung from the clip.
Because our device withheld greater than the 0.7 newtons
requirement it passed the verification #7. To ensure that once
the Chord Fastener was inside the left ventricle there would be
a proper initiation of the clipping mechanism, the material of
the self-expanding Nitinol was used. Its shape change at
different temperature would allow the Chord Fastener to be in
the open temperature at room temperature and in the closed
position at body temperature. This property was used to pass
verification #8 and was tested via vendor descriptions. Then to
ensure that there would be no nickel poisoning from the
Nitinol material used, several stoichiometric calculations were
undertaken to ensure that the percent weight of nickel content
was well below the 0.2 µg/L, fulfilling verification #9. To
make certain that the device was compatible with the catheter,
the team made sure the device could be mounted on a rod.
This was tested via SolidWorks and passed verification # 10.
For verification #11, to ensure that the clip could detach from
the rod, the team used a SolidWorks model to visualize
detachment.
Finally, a Smith & Nephew article on protein adsorption to
different materials was used to verify that the device met the
low to moderate coagulation requirement. This article
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specifically addressed our material of choice, titanium nickel.
In the article the authors analyzed different material surfaces
for a protein adsorption test of fibrinogen and activation of
prekallikrein.
Prekallikrein plays a crucial rule in the coagulation cascade.
Activated prekallikrein will turn into kallikrein. Kallikrein is a
protein that is made from the activation of the factor XIIa [22].
XIIa will turn prekallikrein into kallikrein and factor XI into
XIa which will then lead to the intrinsic pathway [22]. Hence,
prekallikrein is a good indicator for the activation of the
intrinsic pathway.
Fibrinogen is pith for platelet activators and dictates the
adhesion of platelets onto a material [22]. In addition, because
fibrinogen has two receptor binding sites, it plays a crucial
part in allowing for platelet–platelet bridging, this plateletplatelet bridging is what allows for thrombus formation [22].
Thus, looking at levels of fibrinogen adsorption serves as a
great indicator of coagulation and thrombus formation.
The study found that the titanium oxide ceramic surface of Ti13Nb-13Zr, Titanium Nickle, had only 25% of glass’s
prekallikrein activation, where glass was the positive control
group. The study also found that oxide surface of the Titanium
Nickle had a fibrinogen protein adsorption of 20 ng/cm2,
which was only 33% of the positive control group, Biolon's 84
ng/cm2 [18]. In our device will have a titanium oxide layer
that will be exposed to the blood plasma, which is why the
study’s publishing is relative. Since the team’s device
engineering requirement were to have a moderate to low
activation and protein absorption. Thus, this study merited and
verified the use of Nitinol, a Titanium Nickle alloy with a
titanium-oxide surface, for the material of the clip passing
verification # 12.
VII. MEDICAL DEVICE
In the final stage of the design process, the main goal was to
implement any changes made after the design verification. As
was found in the verification testing phase, the major design
change needed was the inclusion of a mechanism for the
device to detach from the catheter. It was determined that this
would be rectified by adding a lock and key design on the
crown of the device. Through use of a SolidWorks Motion
Simulation, it visually showed how when the catheter is
twisted during insertion, it detaches from the crown of the
device.
For images related to validation testing and links to videos,
please see Appendix H.
VIII. VALIDATION TESTING
To certify that the medical device outputs met or exceeded the
user requirements, several validation tests were undertaken,
broken down into two categories: Instron Machine Testing and
SolidWorks flow simulation.
4

Instron Testing
The Instron machine was used to obtain the mechanical
properties of ultimate tensile strength, Young’s modulus,
hysteresis, the coupled viscoelasticity, and effects of load
rates. These properties were obtained by placing the clip onto
bovine muscle tissue.
Testing how the Chord Fastener responds under controlled
loading conditions supplies an understanding of how the
device is expected to behave in a beating heart. Instron
validation testing was done to highlight the clip’s mechanical
properties while gripping the bovine tissue. Load until failure
was done to ensure the breaking strength of the clip was above
the requirement and to obtain the Young’s modulus.
Hysteresis was done to seek energy lost via repeated loading
and unloading.
To test for tensile strength, the sample was loaded onto an
Instron Universal Testing Machine with a 1 kN load cell and
BlueHill3 operating software. The testing machine was
configured with fixtures for a tensile test. Standard protocol
and calibration procedures were followed to accurately set up
the Instron for testing. These procedures can be referenced in
the device’s user manual. The sample was tested under a 12cycle hysteresis test and a load to failure test.
The hysteresis method placed the samples under several
repeated loading and unloading cycles. The test parameters for
the hysteresis test were defined within the Instron software
such that the samples were subjected to a load rate of 0.5
cm/min for a total of 12 cycles. The end condition for the test
was when it completed all 12 cycles.
After completion of the hysteresis test, the Young’s modulus
and tensile strength were obtained using the load until failure.
The test parameters for the test were defined within the Instron
software such that the samples were subjected to a load of
4 N - well above the 0.7 N - at a rate of 0.5 cm/min. There
were two end conditions for the test: a 40% change in rate of
load, which showed the material had fractured, or the
maximum load of 3 N.
The results obtained was an average of 0.15 J lost per 15
cycles, this low value met the cut off requirement of below
0.25 J lost per 15 cycles (which was found to be the average
ratio of energy loss to cycles over a 100,000-cycle period,
with a safety factor of 2). Also, all trials were able to
withstand the 3 N loading with little to no observed slip. These
tests confirm that the device can withstand the dynamic
conditions in the heart, and the device will conserve energy
when in use and negate the energy lost in the valves to the
device. It also validates that our device will withstand the
forces applied onto it by the heart.
Next, a stress relaxation test was undertaken to illustrate that
the devices' implantation did not negate the chordae tendinea’s
May 2021

viscoelastic properties. The clipped tissue was put under a 2 N
constant load for 12 minutes, while observing how the strain
changed with time. Upon ending the test, there was a
significant change in the strain going from 65% to 75% thus
indicating that our setup allows for the tissue to retain its
viscoelastic properties.
Finally, the effect of varying load rate was investigated. A 5cycle hysteresis test was done on 3 separate rates of: 0.5
cm/min, 0.75 cm/min and 1 cm/min, to help capture how our
instrument would react to the varying heart rates of a human
heart. It was found that there was no significant difference in
the energy loss from all 3 trials (as seen in the appendix S).
SolidWorks Flow Simulation
To ensure that the device would not induce a significant drag
or turbulent flow in the mitral valve, thus causing shear stress
induced thrombosis, a SolidWorks simulation was undertaken.
The Chord Fastener’s SolidWorks model along with a pipe of
5 mm length and 3 mm diameter was placed into SolidWorks
Flow simulation. A series of simulations of Cut Plot Velocity,
Surface Plot, Pipe Trajectory and Surface Parameters, were
undertaken to see the flow profile of blood around the device.
There was no qualitative difference in the flow contours
between the simulation with no clip and without clip (as seen
in appendix O and P respectively). Alongside the shear stress
rate without the Chord Fastener was 2.4 dyn/cm2 and
increased to 3.4 dyn/cm2 after its addition. Thus, no significant
difference in shear stress and ultimately supporting that the
clip will not induce thrombosis via shear stress.
IX. RISK MITIGATION PROCESS
Through each step in the design process, the group went
through the process of a Failure Mode and Effects Analysis
(FMEA) model where risks were determined, and mitigations
were developed to help ease or erase risks. Each gate required
a new FMEA to be made as the group made changes to the
design of the device. Risks were determined based on the
design of the device and how it will be used in the human
body. Although there were many risks determined, the most
important risks were the mechanism of clipping the chord, the
design of the crown/legs of the clip, the material that makes up
the clip, and the size of the opened clip. The mechanism of
clipping the chord could cause many issues such as bleeding
or an embolism if the clipping is unsuccessful. This risk was
mitigated by ensuring the surgeon is educated on the clip’s
design. In addition to educating the surgeon, designing the
device’s clips to withstand the forces inside the human heart,
through tensile and fatigue testing, and remain attached to the
chordae tendinea was another mitigation. The design of the
legs and crown of the clip, if not designed based off the forces
in the body, can make the surgery unsuccessful and the clip
could fall off. This was mitigated by the team testing the
device on bovine tissues to ensure it can withstand the tensile
and fatigue forces from a heart. The material of the clip was
5

considered one of the biggest potential problems for the group.
Most patients need to be on an anticoagulant medication after
a surgery that inputs a device in the body due to the foreign
body response that causes coagulation. To prevent this, the
team will use Nitinol, a material that has already been tested in
the body and is moderately successful regarding
anticoagulation when following a natural oxidization of the
material into titanium oxide, following implantation [12]. The
material shows promise because Nitinol was already used for
stents and the MitraClip, but further research will be needed to
validate it for this application. More specifically, protein
adsorption and platelet adhesion tests are needed to evaluate
hemocompatibility [12]. Further options that may be needed
to mitigate that risk are to surface modify the product by
treating it with anticoagulants before insertion or to use the
anticoagulant medication after surgery as a last resort. Recent
studies have showed that surface modification with an
antithrombin-heparin complex is a potential modification that
could be used [10]. The sizing of the clip is the last important
risk that could cause serious issues with the device. Mainly
when the clip is open before clipping onto the chord, the
sizing could cause rubbing against the heart walls which
causes injury and potential bleeding. To mitigate this, the size
of the clip being opened has been mathematically analyzed to
ensure it is smaller than the chamber of the heart it is being
inserted into. Also ensuring the surgeon is educated on how to
use the clip will make sure they also are aware of opening the
clip to its full size (see Appendix I for a risk summary table).
Although there were many risks that could not be completely
mitigated, there are many benefits that outweigh the risks. The
device can save many lives because many people with
elongated chords are elderly and cannot undergo a full openheart surgery. This device will help them to get the care they
need to prevent mitral valve regurgitation. Mitral valve
regurgitation can cause a shorter life expectancy because it
can cause heart failure and other health problems. This device
would help to lengthen a person's life expectancy. The small
risks such as those listed above are considered minor after the
mitigations are added to the design and use of the device. The
small risks associated with the device therefore are
outweighed by the benefits of the device to an individual’s
overall health.
X.

MARKETING AND MANUFACTURING CONSIDERATIONS

In a study conducted in 2016, 598 patients, ages 12 to 81,
were examined after fulfilling the echocardiograph criteria for
mitral valve disease. Of the 598, 33.48% of the patients were
determined to be suffering from elongated CT [3]. If this
percentage is applied to the approximately 4 million patients
with mitral valve regurgitation, it can be estimated that
elongated CT is the cause for around 1.34 million people.
Currently, the average cost of mitral valve replacement and
repair surgery is around $45,000 and $31,000, respectively
[5]. The proposed device would be compatible with the
currently available MitraClip, which costs approximately
$30,000 according to the manufacturer. If offered as a separate
version of this device, the cost would remain similar. If the
May 2021

proposed device is offered as an add-on or separate
attachment, the total cost is estimated to still be under $35,000
when considering the cost of other medical devices made of
nitinol. This cost is still extremely competitive.
XI. SUMMARY FEASABILITY DISCUSSION
This project addressed the clinical need for reducing mitral
valve regurgitation. The proposed device design has the
potential to achieve this through the tightening of elongated
chords that cause valve prolapse. After exploring this problem,
the team realized the benefits of making the procedure
minimally invasive since half the affected patients cannot risk
an open-heart surgery. This is possible with our design in that
the clip can be inserted through a catheter. The clip addresses
the prolapsed valve issue by addressing the problem at its
source, the elongated chord.
The team was able to demonstrate a proof-of-principle device
during this project. It is not classified as a prototype since it
was made at an 8:1 scale out of 3-D printed materials. The
device is still in the very early stages of development. More
extensive testing should involve animal models with a
properly scaled model made of Nitinol. This and further
clinical testing of flow and coagulation will help solidify the
design.
XII. DISCUSSION, LESSONS LEARNED, AND CONCLUSIONS
Lessons Learned
This project helped us to gain knowledge and experience in
the areas of market research, obtaining user requirements,
defining engineering requirements, design development,
testing, prototyping, and device validation. These experiences
will bolster our ability to become practicing engineers. The
technical capabilities we practiced include: 3-D modeling,
analyzing biofluid flow, and conducting statistical analysis.
Skills that are pertinent to being established engineers.
The process of mechanical testing show cased how essential
of a practice it is, as it was used to certify that the device met
user requirements. Our experience derived from the
mechanical testing on the Instron machine is crucial to
understanding examples of key tests used to validate medical
technologies in the enterprise world. In this project the team
was able to use load till failure test as well as hysteresis tests,
to obtain profiles that validated our device. It is the
understanding of these profiles and validation tests that
contributes to medical devices being characterized.
This project allowed the team to build on the undergraduate
career through using hands-on experience. Some of the project
activities included: conducting interviews, doing background
research on the problem of interest and patents relating to
products on the market, working as a team, testing the device,
and prototyping. All of which will prove valuable for intended
professional careers. The research portions of this project
helped increase the knowledge of medical devices as well as
the human body. The project itself allowed us to better
6

understand and to be put through the engineering process of
designing a medical device, like the FMEA, Validation and
Verification processes. Learning the steps of design on paper
only allows so much to be remembered by a student. By doing
the process and walking through each step allows the design
process to be completely solidified in our minds.
The team learned how to use better use SolidWorks software
for a real design application, as well as how to set up, test, and
critically analyze our mechanism’s potential impact on mitral
valve repairs. This project has made a big impact on us
personally and professionally as it offered the opportunity for
us to speak with cardiologists and to see firsthand the
obstacles facing the medical community.
XIII. FUTURE WORK
After successful verification and validation of the design using
the 3-D printed alpha prototype, the team would then make
modifications to make the device compatible with the
MitraClip delivery system or a similar system that allows for
the device to be implanted using minimally invasive
techniques. Also, the team would like to make small
modifications to allow for a small, removable camera to be
attached to give the surgeon better visibility and allow for
better and easier placement of the device. Further testing
would need to be conducted after the device is produced using
Nitinol to show that material differences do not negatively
affect performance.
Individual Roles and Responsibilities
Becca:
In earlier gates, I helped with research of the mitral valve
regurgitation as well as solutions to that problem. I attended
some of the interviews we conducted as well. Throughout
each gate, I played a big part in the FMEAs, deciding the
priorities, severities, occurrences, and how we could fine tune
our device to mitigate risks. I focused on figuring out the risks
and how the design we made could cause issues. From there I
was able to produce ways we could prevent those risks.
Looking at the risks also helped me play a role in researching
to help determine engineering and functional specifications of
the device as we moved towards making a SolidWorks
prototype. Using some simple mathematical equations, I also
did some analysis of the device to get a small look at the
beginnings of forces the device would undergo.
Austin:
In the early stages of the design process, I helped with
researching different causes of mitral regurgitation and the
solutions that were already available. I also helped find
different requirements for our device that would set the goals
for the final design. In the later stages, my focus was on
designing the device using SolidWorks and creating a 3D
printed alpha prototype that could be used for the necessary
testing.
Mary:
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In the first stages of the design process, I helped to research
patents for current devices and attended meetings with
professionals in the field to help derive the engineering
requirements for the project. I also contributed to the QFD and
FMEA documents, helping to figure out which qualities
should have priority and which risks were the most important
to prevent. During verification testing, I performed some of
the testing needed. During validation testing, I acquired some
of the necessary materials needed.
Diana:
Throughout the whole design process, I helped with the first
research process and choosing the project idea. I attended
every interview the team had with stakeholders and faculty
members. Following the user needs stage, I helped develop the
customer and engineering requirements, helped fill out the
QFD and FMEA reports, and supported the group members in
any way that I could. Additionally, I made sure that the design
history file stays updated with all the documents from all
stages, as well as the Gantt chart with all the individual tasks
that were completed.
Walid:
Interviewed Cardiologists to obtain user requirements. Read
many articles and publications, to find the specifications of a
CT repair mechanism. Orchestrated the FMEA for the first
draft, finding some prodigious articles to support our
decisions. Created the verification guidelines. And
orchestrated some of the verifications. Created the Validation
testing procedures and orchestrated the testing of the efficacy
of our device on Instron machines and SolidWorks flow
simulation.
XIV. PROFESSIONAL AND ETHICAL RESPONSIBILITIES
This device has the potential to help change how regurgitation
is treated and allow more people to receive the care they need.
However, this device also has the potential to be harmful or
fatal to the patient if built or designed incorrectly. To prevent
this from happening, extensive research was conducted, and
when possible, the device incorporated already approved
materials and components. Areas of concern included
allergies, scraping of the device against the wall of an artery,
and the possibility of the device slipping and getting dislodged
inside the body.
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APPENDIX

A. Current options for prosthetic heart valves include mechanical or biological valves. The biological valves are either
bovine or porcine valves. The mechanical valves are made of metal.
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B. Quality Functional Deployment (QFD) document. The conditions and criteria to correlate the customer requirements
with engineering requirements were based on information and values found in literature. The relationships assigned were
determined by the design team and they are weak (triangle), moderate (empty circle), or strong (circle with a line in the
middle). The weights of the engineering requirements were calculated by the QFD. Our top 3 Customer Requirements
are bold faced.
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C. Verification Testing Results

Name of Risk

Summary of Risk

Material of Device

The material that makes up
the device causes thrombosis
or coagulation in a patient
which can then cause stroke
or heart attack.

Clipping Mechanism

The clipping of the chord is
unsuccessful, or a slipping
occurs that knocks the clip
out of place.
The design of the crown or
legs does not withstand the
forces of a dynamic heart and
breaks.

Serious
RPN: 144

Ensure there is a surface that
has ridges for friction to hold
the chord in place.

Critical
RPN: 105

The opened clip is too large
and causes a puncture or
rubbing against the heart
wall.

Critical
RPN: 96

Test the device on bovine
tissue using tensile and
fatigue testing to fine tune
dimensions that will
withstand heart forces.
Design the clip so that when
opened it is less than the size
of the chamber it is located
in.

Design of crown/legs

Size of opened clip

May 2021

Risk level and Risk Priority
Number (RPN)
Critical
RPN: 180

Mitigation
Use a material that has
already been tested and
approved for human body
use, surface modify the
product with anticoagulants,
or treat the patient with
medication.
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Spring

The spring does not allow the
Serious
Use the correct spring based
legs to open or close properly
RPN: 28
off its stiffness properties.
rendering the clip useless.
D. Table of risks with descriptions, risk level, and summary of mitigations. Risk priority number (RPN) is determined
through multiplying preassigned numbers based on occurrence, severity, and detection.

E. SolidWorks drawing of the “closed” clip at an 8:1 scale of final product. This scale allows it to be 3D printed.

F.
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SolidWorks drawing of the “open” clip at an 8:1 scale of final product. This scale allows it to be 3D printed.
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G. The apparatus used for Instron machine testing. The following is a link to video of the testing: http://bit.ly/InstronTesting

Part Number Quantity
Name
20-001
1
Clip Base
20-002
1
Clip Shafe
20-003
1
Shaft Guide
20-004
2
Clip Middle
30-001
1
Clip Plate
30-002
2
Clip Int. Arm
40-001
1
Clip Arm - Sm
40-002
1
Clip Arm - Lg
50-001
1
MitraClip Package
60-001
7
Pins

Material
Procurement Type Vendor/Source
Price Each
Nitinol
MTS
FATHOM
requires quote
Nitinol
MTS
FATHOM
requires quote
Nitinol
MTS
FATHOM
requires quote
Nitinol
MTS
FATHOM
requires quote
Nitinol
MTS
FATHOM
requires quote
Nitinol
MTS
FATHOM
requires quote
Nitinol
MTS
FATHOM
requires quote
Nitinol
MTS
FATHOM
requires quote
N/A
OTS
Abbott
~$30,000
Stainless Steel
OTS
McMaster Carr
$3.76

Typical Lead Time
~5 Buisness Days
~5 Buisness Days
~5 Buisness Days
~5 Buisness Days
~5 Buisness Days
~5 Buisness Days
~5 Buisness Days
~5 Buisness Days
unkown
~5 Buisness Days

H. Bill of Materials.
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I.

J.

Gantt Chart of the User Needs stage.

Gantt Chart for the Design Input stage

K. Gantt Chart for the Design Process stage.
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L. Gantt Chart for Design Output stage.

M. Gantt Chart for Medical Device stage.

N. Diagram showing clipping mechanism step-by-step.
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O. Flow Contour Profile with clip

P.
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Flow Contour Profile with NO clip
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Q. Average Energy Loss over the 10+ cycles

R. Stress Relaxation Results
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S.
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Stress Strain graph of varied loading rates
T.
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